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Abstract
Hepatocellular carcinomas (HCCs) are a heterogeneous group of tumors that differ in risk factors and genetic alterations. In
Italy, particularly Southern Italy, chronic hepatitis C virus (HCV) infection represents the main cause of HCC. Using high-
density oligoarrays, we identified consistent differences in gene-expression between HCC and normal liver tissue. Expression
patterns in HCC were also readily distinguishable from those associated with liver metastases. To characterize molecular
events relevant to hepatocarcinogenesis and identify biomarkers for early HCC detection, gene expression profiling of 71
liver biopsies from HCV-related primary HCC and corresponding HCV-positive non-HCC hepatic tissue, as well as
gastrointestinal liver metastases paired with the apparently normal peri-tumoral liver tissue, were compared to 6 liver
biopsies from healthy individuals. Characteristic gene signatures were identified when normal tissue was compared with
HCV-related primary HCC, corresponding HCV-positive non-HCC as well as gastrointestinal liver metastases. Pathway
analysis classified the cellular and biological functions of the genes differentially expressed as related to regulation of gene
expression and post-translational modification in HCV-related primary HCC; cellular Growth and Proliferation, and Cell-To-
Cell Signaling and Interaction in HCV-related non HCC samples; Cellular Growth and Proliferation and Cell Cycle in
metastasis. Also characteristic gene signatures were identified of HCV-HCC progression for early HCC diagnosis.
Conclusions: A diagnostic molecular signature complementing conventional pathologic assessment was identified.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of
cancer death in the world [1–3]. As for other cancers, the etiology
of HCC is multifactorial and progresses through multiple stages
[4]. This multistep process may be divided into chronic liver
injury, inflammation, cell death, cirrhosis, regeneration, DNA
damage, dysplasia and finally HCC. Different lesions have been
considered pre-neoplastic in regard to the development of HCC.
For instance, cirrhotic liver contains regenerative nodules and like
HCC may contain dysplastic nodules [5,6]. The principal risk
factor for the development of HCC is hepatitis B virus (HBV)
[7,8], followed by hepatitis C virus (HCV) infection [9]. Non viral
causes are less frequent and include toxins and drugs (e.g., alcohol,
aflatoxins, microcystin, anabolic steroids), metabolic liver diseases
(e.g., hereditary haemochromatosis, a1-antitrypsin deficiency),
steatosis [10] and non-alcoholic fatty liver disease [11,12]. In
general, HCCs are more prevalent in men than in women and the
incidence increases with age.
The molecular mechanism underlying HCC is currently
unknown. Activation of cellular oncogenes, inactivation of
tumor suppressor genes, over-expression of growth factors,
possibly telomerase activation and DNA mismatch repair defects
may contribute to the development of HCC. Alterations in gene
expression patterns accompanying different stages of growth,
disease initiation, cell cycle progression, and responses to
environmental stimuli provide important clues to these complex
process [13,14]. In addition to primary HCC, metastatic liver
disease often occurs. Metastases most often derive from
gastrointestinal organs, primarily colon and rectum, though
they can occur from primaries throughout the body [15]. These
cancers can be treated using routine therapies relevant to the
primary such as chemotherapy, radiotherapy, surgical resection,
liver transplantation, chemo-embolization, cryosurgery or com-
bination therapy [16]. The characterization of genes that are
differentially expressed during tumorigenesis is an important
step toward the identification of the biological steps involved in
the transformation process. Studies examining the gene expres-
sion of metastatic liver tumors and HCC in parallel with paired
non-cancerous liver tissues might yield important insights by
identifying genes not expressed in normal liver and are switched
on in tumors and vice versa. Such studies should also lead to
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the identification of genes that are expressed in tumors at
different stages and never in non cancerous liver tissue.
The present study assessed the expression profile of 18 HCV-
related primary HCCs and their corresponding HCV-positive
non-HCC counterpart, 1 HCV-positive liver sample without the
corresponding HCC tissue, 14 gastrointestinal liver metastases and
their corresponding non cancerous tissue and 6 liver biopsies from
patients with benign pathologies and normal liver by use of high-
density oligonucleotide arrays. This represents an independent
study from a previous study performed by our group [17]. An
HCC-specific molecular signature set was identified that may
enhance conventional pathologic assessment and may provide a
tool for prognostic purposes, as well as identify targets for new
therapeutic strategies.
Materials and Methods
Patient and Tissue Samples
A total of 102 liver human samples have been analyzed.
Thirty one samples were used to define the signature genes in
the first group of samples represented by a subset of samples
from 19 patients profiled and reported in a previous study of
molecular classification of HCV-related hepatocellular carcino-
ma [17]. An independent set of 71 liver biopsies has been used
to define/evaluate the identified liver cancer signature (Figure 1).
Liver biopsies from 19 HCV-positive HCCs, 14 metastases
from distant primary and 6 HCV-negative control samples from
healthy donors obtained during laparoscopic cholecystectomy
were obtained with informed consent at the liver unit of the
INT ‘‘Pascale’’, Naples. In addition from each of the HCV-
positive HCC and metastatic patients a paired liver biopsy from
non-adjacent, non-tumor containing liver was obtained. All liver
biopsies were stored in RNA Later at 280Cu (Ambion,
Austin,TX). Confirmation of the histopathological nature of
the biopsies was performed by the Pathology lab at INT before
processing samples for RNA extraction. The non-HCC tissues
from HCV-positive patient represented a heterogeneous sample
consistent with the prevalent liver condition of each subject
(ranging from persistent HCV-infection to cirrhotic lesions). One
HCC sample, was shown to be mainly cirrhotic tissue and
removed from the analysis. Furthermore, laboratory analysis
confirmed that the 6 controls were seronegative for HCV
antibodies.
Figure 1. Study design. Gene signature distinguishing the different pathological stage of liver disease and potential molecular progression
markers was defined in the first dataset (left panel) and defined/evaluated in the independent second dataset (right panel).
doi:10.1371/journal.pone.0056153.g001
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Figure 2. Unsupervised hierarchical clustering: Panel A. Heat map based on 8,210 genes of 71 liver samples (HCV-related HCC, non-HCC
counterpart, metastases, non cancerous counterpart and controls from healthy donors). Genes were filtered according to the following criteria:
presence in 80% of all experiments, a .3 fold change ratio in at least one experiment. Red indicates over-expression; green indicates under-
expression; black indicates unchanged expression; gray indicates no detection of expression (intensity of both Cy3 and Cy5 below the cutoff value).
Each row represents a single gene; each column represents a single sample. The dendrogram at the top of the matrix indicates the degree of
similarity between samples. Panel B Principal Component Analysis (PCA) 3D view for gene expression profiles from 71 liver samples. The PCA is
based on log2 ratios and the expression profiles are across all the 36,000 genes in the microarrays. The green, blue, red, purple, and orange dots
indicate metastasis, HCV-related HCC, HCV related non HCC, non metastatic counterpart, HCV-negative normal control and samples, respectively.
doi:10.1371/journal.pone.0056153.g002
Figure 3. Heatmap of the genes differentially expressed: identified by Class ComparisonAnalysis. Analysis including HCV-related HCC and normal
liver samples from control subjects (Panel A); analysis including HCV-related non-HCC liver tissues and liver samples from control subjects (Panel B); analysis
including liver metastasis and liver samples from control subjects (Panel C); analysis including HCV-related HCC and their HCV-positive/cirrhotic counterpart
(Panel D); analysis including all HCV-related HCC, their HCV-positive/cirrhotic counterpart and normal liver samples, each column represents the average of all
samples belonging to the same group as it was a single array (Panel E). The expression pattern of the genes is shown, each row representing a single gene.
doi:10.1371/journal.pone.0056153.g003
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Table 1. Gene Set Characterizing HCV related HCC Samples.
First Dataset Second Dataset
UGCluster Gene Name Description p-value Fold-Change p-value Fold-Change
Hs.437126 ARHGAP9 Rho GTPase activating protein 9 0.000778 3.26 0.000521 2.27
Hs.127799 BIRC3 Baculoviral IAP repeat-containing 3 0.007263 2.30 0.000341 2.12
Hs.488143 BLVRA Biliverdin reductase A 0.001564 2.34 0.006145 2.20
Hs.143733 CCDC34 Coiled-coil domain containing 34 0.009417 2.02 0.003457 2.11
Hs.173724 CKB Creatine kinase, brain 0.00582 2.45 0.000255 2.36
Hs.713537 GPC3 Glypican 3 0.005205 3.32 0.006609 2.82
Hs.488189 H2AFV H2A histone family, member V 2.50E205 2.42 0.000491 2.33
Hs.519972 HLA-F Major histocompatibility complex, class I, F 0.003041 2.18 0.001327 2.18
Hs.380250 IFI16 Interferon, gamma-inducible protein 16 0.008685 2.65 2.48E208 2.69
Hs.532634 IFI27 Interferon, alpha-inducible protein 27 7.06E205 3.43 0.000336 4.98
Hs.458485 ISG15 ISG15 ubiquitin-like modifier 0.004877 3.46 0.005316 5.00
Hs.535903 JRK Jerky homolog 0.002148 2.24 1.21E205 2.40
Hs.107125 PLVAP Plasmalemma vesicle associated protein 0.009883 2.48 0.004255 2.21
Hs.658434 PSIP1 PC4 and SFRS1 interacting protein 1 0.000938 3.08 1.59E206 3.54
Hs.654402 RELB V-rel reticuloendotheliosis viral oncogene homolog B 0.002434 2.06 0.000175 2.25
Hs.381167 SERPINB1 Serpin peptidase inhibitor 0.002656 2.19 0.000266 2.13
Hs.327527 SMARCA4 SWI/SNF related 0.006768 2.02 0.002634 2.16
Hs.708051 STAT1 Signal transducer and activator of transcription 1, 91 kDa 1.58E206 4.03 0.000374 3.02
Hs.352018 TAP1 Transporter 1, ATP-binding cassette 0.002018 2.34 0.000257 2.67
Hs.653181 THY1 Thy-1 cell surface antigen 0.00094 4.89 0.005523 3.24
Hs.515122 TK1 Thymidine kinase 1 0.002458 2.82 0.000584 2.21
Hs.714406 UBD Ubiquitin D 0.002593 3.72 0.000516 3.80
doi:10.1371/journal.pone.0056153.t001
Table 2. Gene Set Characterizing HCV related non HCC Samples.
First Dataset Second Dataset
UGCluster Gene Name Description p-value Fold-Change p-value Fold-Change
Hs.497399 ARL8A ADP-ribosylation factor-like 8A 0.000161 2.51 0.006094 2.66
Hs.496983 HCG4 HLA complex group 4 3.64E205 2.49 7.40E206 2.07
Hs.529317 HERC6 Hect domain and RLD 6 5.20E205 2.28 0.001327 2.14
Hs.591798 HLA-DQA2 Major histocompatibility complex, class II, DQ alpha 2 0.006389 2.03 0.005283 2.01
Hs.519972 HLA-F Major histocompatibility complex, class I, F 4.84E205 3.02 0.000372 2.33
Hs.512152 HLA-G Major histocompatibility complex, class I, G 0.001323 2.09 0.001857 5.44
Hs.655226 HLA-H Major histocompatibility complex, class I 0.000177 2.53 0.000776 2.24
Hs.532634 IFI27 Interferon, alpha-inducible protein 27 5.25E207 5.12 0.008629 3.37
Hs.523847 IFI6 Interferon, alpha-inducible protein 6 0.000191 3.95 0.006532 3.81
Hs.458485 ISG15 ISG15 ubiquitin-like modifier 0.000179 5.59 0.000515 6.69
Hs.479384 KIAA0746 KIAA0746 protein 0.001081 2.37 0.002704 2.10
Hs.517307 MX1 Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 0.001325 3.09 3.40E206 6.02
Hs.524760 OAS1 2’,5’-oligoadenylate synthetase 1, 40/46 kDa 0.000247 2.73 0.001017 2.56
Hs.118633 OASL 2’–5’-oligoadenylate synthetase-like 0.000174 2.77 0.000355 3.29
Hs.708051 STAT1 Signal transducer and activator of transcription 1, 91 kDa 7.86E209 6.04 0.000204 4.51
Hs.352018 TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 0.000245 2.86 9.60E205 2.83
Hs.714406 UBD Ubiquitin D 0.002371 3.69 0.002236 2.83
Hs.38260 USP18 Ubiquitin specific peptidase 18 0.008324 2.13 0.006233 2.49
doi:10.1371/journal.pone.0056153.t002
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RNA Isolation, cDNA Synthesis, in vitro Transcription and
aRNA Labeling
Samples were homogenized in disposable tissue grinders
(Kendall, Precision). Total RNA was extracted by TRIzol solution
(Life Technologies, Rockville, MD), and purity of the RNA
preparation was verified evaluating the 260:280 nm ratio of the
spectrophotometric reading with NanoDrop (Thermo Fisher
Scientific, Waltham, MA). Moreover, the integrity of extracted
RNA was evaluated by Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA), analyzing the presence of 28S and
18S ribosomal RNA bands and verifying that the 28S/18S rRNA
intensity ratio was equal or close to 1.5. In addition, phenol
contamination was evaluated considering acceptable a
260:230 nm OD ratio within a 2.0–2,2 range.
Double-stranded complementary DNA (cDNA) was prepared
from 3 mg of total RNA (T-RNA) in 9 ml DEPC -treated H2O
using the Super script II Kit (Invitrogen) with a T7-(dT15)
oligonucleotide primer. cDNA synthesis was completed at 42uC
for 1 h. Full-length dsDNA was synthesized incubating the
produced cDNA with 2 U of RNase-H (Promega) and 3 ml of
Advantage cDNA Polymerase Mix (Clontech), in Advantage PCR
buffer (Clontech), in presence of 10 mM dNTP and DNase-free
water. dsDNA was extracted with phenol–chloroform–isoamyl,
precipitated with ethanol in the presence of 1 ml linear acrylamide
(0.1 mg/ml, Ambion, Austin, TX) and aRNA (amplified-RNA) was
synthesized using Ambion’s T7 MegaScript in Vitro Transcription
Kit (Ambion, Austin, TX). aRNA recovery and removal of
template dsDNA was achieved by TRIzol purification. For the
second round of amplification, aliquots of 1 mg of the aRNA were
reverse transcribed into cDNA using 1 ml of random hexamer
under the conditions used in the first round. Second-strand cDNA
synthesis was initiated by 1 mg oligo-dT-T7 primer and the
resulting dsDNA was used as template for in vitro transcription of
aRNA in the same experimental conditions as for the first round
[18]. 6 mg of this aRNA was used for probe preparation, in
particular test samples were labeled with USL-Cy5 (Kreatech) and
pooled with the same amount of reference sample (control donor
peripheral blood mononuclear cells, PBMC, seronegative for anti-
hepatitis C virus (HCV) antibodies ) labeled with USL-Cy3
(Kreatech).The two labeled aRNA probes were separated from
unincorporated nucleotides by filtration, fragmented, mixed and
co-hybridized to a custom-made 36K oligoarrays at 42Cufor 24 h.
The oligo-chips were printed at the Immunogenetics Section,
Department of Transfusion Medicine, Clinical Center, National
Institutes of Health (Bethesda, MD). After hybridization the slides
were washed with 2xSSC/0.1%SDS for 1 min, 1xSSC for 1 min,
0.2xSSC for 1 min, 0.056SSC for 10 sec., and dried by
centrifugation at 800 g for 3 minutes at RT.
Data Analysis
Hybridized arrays were scanned at 10-mm resolution with a
GenePix 4000 scanner (Axon Instruments) at variable photo-
multiplier tube (PMT) voltage to obtain maximal signal intensities
with less than 1% probe saturation. Image and data files were
deposited at microarray data base (mAdb) at http://madb.nci.nih.
gov and retrieved after median centered, filtering of intensity
(.200) and spot elimination. Data were further analyzed using
Cluster and TreeView software (Stanford University, Stanford,
CA).
Statistical Analysis
Unsupervised Analysis. For this analysis, a low-stringency
filtering was applied, selecting the genes differentially expressed in
80% of all experiments with a .3 fold change ratio in at least one
experiment. 8,210 genes were selected for the analysis including
the five groups of analyzed samples the HCV-related HCC, their
non-HCC counterpart, metastasis, and their non metastatic
counterpart as well as samples from the normal controls.
Hierarchical cluster analysis was conducted on these genes
according to Eisen et al. [19], differential expressed genes were
visualized by Treeview and displayed according to the central
method [20]. Principal component analysis (PCA) was applied for
visualization when relevant based on the complete dataset.
Supervised Analysis. Supervised class comparison was
performed using the BRB ArrayTool developed at NCI, Biometric
Research Branch, Division of Cancer Treatment and Diagnosis.
Three subsets of genes were explored. The first subset included
genes up-regulated in HCV-related HCC compared to normal
control samples, the second subset included genes up-regulated in
the HCV-related non-HCC counterpart compared with normal
control samples, the third subset included genes up-regulated in
metastasis compared with normal control samples. Paired samples
were analyzed using a two-tailed paired Student’s t-Test. Unpaired
samples were tested with a two-tailed unpaired Student’s t-Test
assuming unequal variance or with an F-test as appropriate. All
analyses were tested for an univariate significance threshold set at
a p-value ,0.01. Gene clusters identified by the univariate t-test
were challenged with two alternative additional tests, a univariate
permutation test (PT) and a global multivariate PT. The
multivariate PT was calibrated to restrict the false discovery rate
to 10%. Genes, identified by univariate t-test as differentially
expressed (p-value ,0.01) and a PT significance ,0.05, were
considered truly differentially expressed. Gene function was
Table 3. Gene Set Characterizing HCC Samples compared with autologous tissue.
First Dataset Second Dataset
UGCluster Gene Name Description p-value Fold-Change p-value Fold-Change
Hs.440961 CAST Calpastatin 0.009947 1.64 4.79E206 1.58
Hs.93836 DFNB31 Deafness, autosomal recessive 31 0.008123 1.54 0.002648 1.57
Hs.22785 GABRE Gamma-aminobutyric acid (GABA) A receptor, epsilon 0.002371 2.12 0.005056 3.41
Hs.488189 H2AFV H2A histone family, member V 0.001511 1.72 2.31E205 1.62
Hs.485938 RRAGD Ras-related GTP binding D 0.000427 1.73 0.000292 1.66
Hs.407856 SPINK1 Serine peptidase inhibitor, Kazal type 1 5.31E206 14.49 0.002134 4.12
Hs.164070 THEM4 Thioesterase superfamily member 4 0.008042 1.57 0.000359 1.61
doi:10.1371/journal.pone.0056153.t003
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Table 4. Gene Set Characterizing Metastatic Samples.
UGCluster Gene Name Description p-value Fold-Change
Hs.529353 ACSS1 Acyl-CoA synthetase short-chain family member 1 3.99E208 4.40
Hs.514581 ACTG1 Actin, gamma 1 2.01E208 3.32
Hs.530009 AGR2 Anterior gradient homolog 2 0.00026377 3.89
Hs.270833 AREG Amphiregulin 3.82E205 3.82
Hs.701324 ARHGAP4 Rho GTPase activating protein 4 1.01E207 2.59
Hs.371889 ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 6.78E208 2.98
Hs.591382 BSG Basigin 1.05E207 2.93
Hs.8859 CANT1 Calcium activated nucleotidase 1 8.44E206 2.90
Hs.523852 CCND1 Cyclin D1 7.16E206 3.28
Hs.82916 CCT6A Chaperonin containing TCP1, subunit 6A (zeta 1) 1.06E208 4.3
Hs.502328 CD44 CD44 molecule 0.00033064 2.16
Hs.114286 CD9 CD9 molecule 4.99E207 3.53
Hs.709226 CDH3 Cadherin 3, type 1, P-cadherin 2.32E207 3.37
Hs.712603 CENPO Centromere protein O 4.28E209 2.92
Hs.173724 CKB Creatine kinase, brain 7.68E209 5.14
Hs.414565 CLIC1 Chloride intracellular channel 1 4.93E207 3.23
Hs.443625 COL3A1 Collagen, type III, alpha 1 8.67E207 6.38
Hs.17441 COL4A1 Collagen, type IV, alpha 1 1.20E206 5.41
Hs.570065 COL4A3 Collagen, type IV, alpha 3 (Goodpasture antigen) 0.00010556 3.13
Hs.2242 CSN2 Casein beta 1.69E205 3.20
Hs.67928 ELF3 E74-like factor 3 1.60E205 3.01
Hs.655278 FER1L3 Fer-1-like 3, myoferlin 4.01E208 2.86
Hs.443687 FHL2 Four and a half LIM domains 2 1.35E205 3.20
Hs.499659 GARNL4 GTPase activating Rap/RanGAP domain-like 4 2.00E207 4.21
Hs.203699 GOLPH3L Golgi phosphoprotein 3-like 6.84E209 12.95
Hs.231320 GPR160 G protein-coupled receptor 160 4.64E208 3.70
Hs.2704 GPX2 Glutathione peroxidase 2 4.41E206 2.81
Hs.523836 GSTP1 Glutathione S-transferase pi 2.26E207 6.93
Hs.31720 HEPH Hephaestin 1.35E205 3.96
Hs.594238 KPNA2 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 0.00037649 2.15
Hs.406013 KRT18 Keratin 18 1.74E206 5.81
Hs.374191 LEPREL1 Leprecan-like 1 3.36E205 10.35
Hs.5302 LGALS4 Lectin, galactoside-binding, soluble, 4 (galectin 4) 2.74E205 2.59
Hs.444118 MCM6 Minichromosome maintenance complex component 6 7.33E209 2.66
Hs.632177 MVP Major vault protein 6.08E207 2.59
Hs.533282 NONO Non-POU domain containing, octamer-binding 4.45E208 2.55
Hs.406515 NQO1 NAD(P)H dehydrogenase, quinone 1 0.00017945 9.82
Hs.553765 OR4K17 Olfactory receptor, family 4, subfamily K, member 17 3.42E205 3.57
Hs.154104 PLAGL2 Pleiomorphic adenoma gene-like 2 2.41E208 2.50
Hs.155342 PRKCD Protein kinase C, delta 4.30E208 2.52
Hs.499094 PYCARD PYD and CARD domain containing 6.41E207 2.52
Hs.714383 RAPGEFL1 Rap guanine nucleotide exchange factor (GEF)-like 1 0.00091543 2.67
Hs.449968 RHCE Rh blood group, CcEe antigens 0.00022816 3.64
Hs.653288 RNF12 Ring finger protein 12 7.53E209 2.78
Hs.381061 RPL19 Ribosomal protein L19 2.49E208 2.77
Hs.514196 RPL27 Ribosomal protein L27 1.36E208 2.63
Hs.178551 RPL8 Ribosomal protein L8 3.73E207 2.56
Hs.356502 RPLP1 Ribosomal protein, large, P1 2.73E207 2.88
Hs.118076 RPS4X Ribosomal protein S4, X-linked 1.03E208 2.51
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assigned based on Database for Annotation, Visualization and
Integrated Discovery (DAVID) and Gene Ontology (http://www.
geneontology.org/).
Time course analysis. A time course analysis was per-
formed to identify markers of tumoral progression between normal
liver samples, HCV-related non HCC and HCV-related HCC
liver samples. For this analysis, normal liver samples (CTR) were
taken as the early time point, HCV-related non HCC as the
intermediate point and the HCV-related HCC as the last time
point. Parameters for gene selection were: F test p-value ,0.005,
80% presence call, ratio of .2 and false discovery rate ,0.1.
Ingenuity pathway analysis IPA). Pathway analysis was
performed using the gene set expression comparison kit imple-
mented in BRB-Array- Tools. The human pathway lists deter-
mined by ‘‘Ingenuity System Database’’ was selected. Significance
threshold of t-test was set at 0.01. IPA is a system that transforms
large dataset into a group of relevant networks containing direct
and indirect relationships between genes based on known
interactions in the literature. The significance of each network
was estimated by the scoring system provided by Ingenuity. The
scores are determined by the number of differentially expressed
genes within each of the networks and the strength of the
associations among network members.
Results
Genes Differentially Expressed among Distinct Tissues
The gene expression profile- of tissue samples from the various
groups (HCV-related HCC, non-HCC counterpart, metastases,
non-metastatic counterpart and controls from healthy donors) were
compared by unsupervised analysis. Genes were filtered according
to the following criteria: presence in 80% of all experiments, a .3
fold change ratio in at least one experiment; this filter yielded 8,210
genes that were used for clustering. The HCC and the metastatic
samples prevalently clustered into distinct groups, based on
differences in their patterns of gene expression (Figure2A). PCA
segregated the different sample types into four-five groups according
on their pathological status. Statistical and functional analysis of the
profiles identified a set of genes whose expression was differentially
altered between the groups (Figure 2B). The expression pattern of
gastrointestinal liver metastases was clearly distinct from that of
HCV-related primary HCC, allowing a definite molecular charac-
terization of the two diseases.
Differential Gene Expression Patterns between HCV
positive Liver Tissue with and without HCC, Metastasis
and Normal control Liver Tissue
An unpaired Student’s t-test with a cut-off p value set at p,0.01
comparing HCV-related HCC to normal controls indentified 1864
genes differentially expressed. Among them, 993 were up-regulated
and 871 down-regulated in HCV-related HCCs (Figure 3A).
In total 198 genes showing up regulation were found in
common with our previous study [17], the results is presented as
two-way Venn diagram in additional Figure S1A and Supple-
mental Table S1. The common genes 2.0 fold upregulated (ranked
according to the name) are listed in Table 1.
Comparison between liver tissues from HCV-related non HCC
and normal controls (p,0.01) indentifies 1526 genes differentially
expressed. Among them, 618 were up-regulated and 918 down-
regulated in HCV-related HCC liver tissues (Figure 3B). In total
59 genes showing up regulation were found in common with our
previous study [17], the results is presented as two-way Venn
diagram in additional Figure S1B and Supplemental Table S1.
The common genes 2.0 fold upregulated (ranked according to the
name) are listed in Table 2.
Table 4. Cont.
UGCluster Gene Name Description p-value Fold-Change
Hs.546287 RPS7 Ribosomal protein S7 6.38E206 2.91
Hs.449909 RPSA Ribosomal protein SA 1.02E208 2.61
Hs.381167 SERPINB1 Serpin peptidase inhibitor 2.56E209 3.70
Hs.111779 SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 1.69E207 2.87
Hs.31439 SPINT2 Serine peptidase inhibitor, Kunitz type, 2 1.44E208 3.46
Hs.643338 SPOCK1 Sparc/osteonectin 0.00063078 3.91
Hs.352018 TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 4.87E206 2.68
Hs.12956 TAX1BP3 Tax1 (human T-cell leukemia virus type I) binding protein 3 1.03E205 2.76
Hs.529618 TFRC Transferrin receptor (p90, CD71) 2.13E205 2.81
Hs.529618 TFRC Transferrin receptor (p90, CD71) 2.13E205 2.81
Hs.522632 TIMP1 TIMP metallopeptidase inhibitor 1 5.26E208 4.92
Hs.515122 TK1 Thymidine kinase 1, soluble 1.51E207 4.03
Hs.89643 TKT Transketolase (Wernicke-Korsakoff syndrome) 0.00026987 2.93
Hs.513058 TMED3 Transmembrane emp24 protein transport domain containing 3 2.34E207 3.28
Hs.46720 TMPRSS5 Transmembrane protease 8.05E205 2.50
Hs.446574 TMSB10 Thymosin beta 10 2.65E207 2.91
Hs.370515 TRIM5 Tripartite motif-containing 5 1.17E206 2.71
Hs.654595 VIL1 Villin 1 2.17E205 3.08
Hs.128548 VIM WD repeat domain 1 4.79E205 2.57
Hs.301094 ZNF629 Zinc finger protein 629 6.47E205 2.58
doi:10.1371/journal.pone.0056153.t004
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Table 5. Gene-signature of HCC progression.
UGCluster Name Symbol
Hs.654433 Alcohol dehydrogenase 1A (class I), alpha polypeptide ADH1A
Hs.477887 Angiotensin II receptor, type 1 AGTR1
Hs.116724 Aldo-keto reductase family 1, member B10 AKR1B10
Hs.9613 Angiopoietin-like 4 ANGPTL4
Hs.374774 Ankyrin repeat domain 29 ANKRD29
Hs.633003 Apolipoprotein A-I APOA1
Hs.440934 Arginase, liver ARG1
Hs.486031 Activating signal cointegrator 1 complex subunit 3 ASCC3
Hs.98338 Aurora kinase C AURKC
Hs.80756 Betaine-homocysteine methyltransferase BHMT
Hs.356440 Coiled-coil domain containing 72 CCDC72
Hs.575869 Complement factor H-related 1 CFHR1
Hs.591464 Cingulin CGN
Hs.268326 C-type lectin domain family 2, member D CLEC2D
Hs.220649 C-type lectin superfamily 4, member G CLEC4G
Hs.172928 Collagen, type I, alpha 1 COL1A1
Hs.508716 Collagen, type IV, alpha 2 COL4A2
Hs.522891 Chemokine (C-X-C motif) ligand 12 CXCL12
Hs.590921 Chemokine (C-X-C motif) ligand 2 CXCL2
Hs.706262 Decorin DCN
Hs.476453 Deoxyribonuclease I-like 3 DNASE1L3
Hs.80552 Dermatopontin DPT
Hs.224171 Enolase 3 (beta, muscle) ENO3
Hs.27836 Fibronectin type III domain containing 4 FNDC4
Hs.25647 V-fos FBJ murine osteosarcoma viral oncogene homolog FOS
Hs.78619 Gamma-glutamyl hydrolase GGH
Hs.518525 Glutamate-ammonia ligase GLUL
Hs.713537 Glypican 3 GPC3
Hs.190783 Histidine ammonia-lyase HAL
Hs.190783 Histidine ammonia-lyase HAL
Hs.659767 Hydroxyacid oxidase 2 HAO2
Hs.59889 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 HMGCS2
Hs.532634 Interferon, alpha-inducible protein 27 IFI27
Hs.523414 Insulin-like growth factor 2 (somatomedin A) IGF2
Hs.709180 Netrin 2-like (chicken) IGKC
Hs.632629 Indolethylamine N-methyltransferase INMT
Hs.657894 IQ motif containing H IQCH
Hs.458485 ISG15 ubiquitin-like modifier ISG15
Hs.76716 Inter-alpha (globulin) inhibitor H3 ITIH3
Hs.77741 Kininogen 1 KNG1
Hs.77741 Kininogen 1 KNG1
Hs.492314 Lysosomal associated protein transmembrane 4 beta LAPTM4B
Hs.130767 Leucine rich repeat containing 46 LRRC46
Hs.482087 Leucine rich repeat containing 8 family, member D LRRC8D
Hs.514402 Protein kinase LYK5 LYK5
Hs.201083 Mal, T-cell differentiation protein 2 MAL2
Hs.349110 Macrophage stimulating 1 (hepatocyte growth factor-like) MST1
Hs.512587 Macrophage stimulating 1 (hepatocyte growth factor-like) MST1
Hs.512973 Protein tyrosine phosphatase-like A domain containing 1 PTPLAD1
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Comparison between liver tissues from HCV-related HCC and
parental HCV-related non HCC (p,0.01) indentifies 1020 genes
differentially expressed. Among them, 468 were up-regulated and
552 down-regulated in HCV-related HCC liver tissues (Figure 3C).
In total 10 genes showing up regulation were found in common
with our previous study [17], the results is presented as two-way
Venn diagram in additional Figure S1C and Supplemental Table
S1. The common genes 2.0 fold upregulated (ranked according to
the name) are listed Table 3.
Comparison of liver tissues from metastases and normal controls
(p,0.01) indentified 1,780 genes. Among them, 760 were shown
to be up-regulated and 860 down-regulated in metastatic liver
tissues (Figure 3D and Supplemental Table S2). The genes
showing the highest fold up-regulation are listed in Table 4.
Gene Signatures Involved in HCC progression
A progression of differences in gene expression across tissue
types from normal (n = 6) to HCV related non HCC (n = 19) to
HCV-related HCC (n = 18) identified 450 genes with decreasing
and 136 genes with increasing trend in expression (Figure 3E).
Genes with a significantly increasing trend in expression values
were considered as possible diagnostic and prognostic markers.
The genes showing the highest fold of up-regulation that were also
consistent with our previous findings [17] are reported in Table 5.
Canonical Pathways and Molecular and Cellular
Functions
To explore the biological significance of the genes character-
izing different pathological or normal conditions we investigated
their interactions by IPA mapping their molecular/cellular
functions and canonical pathways. The more important molecular
and cellular functions (ranked according to lowest p value) of genes
up-regulated in HCV-related HCC samples were related to
regulation of gene expression (1.12E217 to 3.41E203), cellular
growth and proliferation (2.00E214 to 3.84E203) and post-
translational modification (1.53E209 to 2.45E203). The top
canonical pathways included protein ubiquitination
(p=2.88E203), 14-3-3 mediated Signaling (p= 1.13-E02) and
Aryl Hydrocarbon receptor signaling pathway (p=3.09E-02)
(Figure 4A). The more important molecular and cellular functions
(High p value) of genes up-regulated in HCV-related non HCC
samples were related to Cellular Growth and Proliferation (1.04E-
22 to 4.61E204), Gene Expression (2.07E222 to 4.58E204) and
Cell-To-Cell Signaling and Interaction (9.05E214 to 4.65E204).
The top canonical pathways included Interferon Signaling Genes
(p=9.78E204), Antigen Presentation Pathway (p = 1.58E203)
and Protein Ubiquitination Pathway (p = 2.44E202) (Figure 4B).
The more important molecular and cellular functions (High p
value) of genes up-regulated in metastases were related to Gene
Expression (6.08E226 to 2.00E204), Cellular Growth and
Proliferation (1.86E225 to 8.64E205), Cell Cycle (5.67E221 to
1.33E204). The top canonical pathways included Arginine and
Proline Metabolism (p = 1.77E209), Coagulation System
(p = 9.68E209) and Acute Phase Response Signaling
(p = 2.08E208) (Figure 4C). Table 6 summarizes the more
important findings for each of the described comparison analysis.
Among the three different class comparison analysis (HCV-
related HCC, HCV-related non HCC and Metastatic liver tissue
vs normal control) we found a gene-set that distinguish the
different cases of liver disease, in particular with time course
analysis we identify the genes that should be candidate as a
possible progression markers (Figure 5).
Discussion
HCC is a common and aggressive malignant tumor worldwide
with a dismal outcome. Early detection and resection may offer an
opportunity to improve the long-term survival for HCC patients.
Unfortunately, with current diagnostic approaches, only about 10%
to 20% of HCC patients are eligible for resection [21]. In the first
study, microarray analyses of liver biopsies from HCC nodules and
paired non-adjacent non-HCC liver tissue of the same HCV-positive
patients were compared to biopsies from HCV-negative control
subjects. The class comparison analysis used in that study successfully
identified a set of genes significant differentially expressed. Moreover
Table 5. Cont.
UGCluster Name Symbol
Hs.334587 RNA binding protein with multiple splicing RBPMS
Hs.375142 Ral guanine nucleotide dissociation stimulator-like 3 RGL3
Hs.633703 Ring finger protein 125 RNF125
Hs.558396 Stearoyl-CoA desaturase (delta-9-desaturase) SCD
Hs.275775 Selenoprotein P, plasma, 1 SEPP1
Hs.702168 Shroom family member 3 SHROOM3
Hs.167584 Solute carrier family 2 (facilitated glucose transporter), member 2 SLC2A2
Hs.407856 Serine peptidase inhibitor, Kazal type 1 SPINK1
Hs.708051 Signal transducer and activator of transcription 1, 91kDa STAT1
Hs.333132 Tudor domain containing 1 TDRD1
Hs.516578 Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) TFPI
Hs.653181 Thy-1 cell surface antigen THY1
Hs.184194 Transmembrane 4 L six family member 5 TM4SF5
Hs.596726 Transmembrane protein 106C TMEM106C
Hs.85524 Tripartite motif-containing 55 TRIM55
Hs.714406 Ubiquitin D UBD
doi:10.1371/journal.pone.0056153.t005
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the up-regulated genes identified within the individual class
comparison analysis were evaluated and classified by a pathway
analysis, according to the "Ingenuity System Database".
The genes up-regulated in samples fromHCV-related HCCwere
classified in metabolic pathways, and the most represented are the
Aryl Hydrocarbon receptor signaling (AHR) and, protein Ubiqui-
tination pathways, which have been previously reported to be
involved in cancer, and in particular in HCC, progression. The
genes up-regulated in samples from HCV-related non-HCC tissue
were classified in several pathways prevalently associated to
inflammation and native/adaptive immunity and most of the over
expressed genes belong to the Antigen Presentation pathway. In this
new study we performed the same statistical analysis under the same
condition to confirm our previous data. To elucidate the genes and
molecular pathways involved in the HCV-related HCC a class
comparisons analysis were performed on new samples set. This
analysis allowed us to identify the unique probe sets characterizing
the pathological status, in fact as expected, the gene expression
patterns were found to vary significantly among the HCC and
normal control liver samples. Genes associated with cell death, cell
to cell signaling and interaction, were found to have increased
expression in HCC samples. The molecular events linked to the
development and progressions of HCC are not well known.
Malignant hepatocytes are the result of sequential changes
accumulated in mature hepatocytes or can derive from stem cells.
The most accepted hypotheses [22,23] describes a step-by-step
process in which external stimuli induce genetic alterations in
mature hepatocytes leading to cell death, cellular proliferation, and
the production of monoclonal populations. These populations
harbor dysplastic hepatocytes that evolve to dysplastic nodules [24].
Canonical pathways prevalently associated with HCV-related
HCC included protein ubiquitination, antigen presentation and
Aryl Hydrocarbon receptor signaling pathway, confirming our
previous data.
Figure 4. Ingenuity Pathways analysis: significant pathways at the nominal 0.01 level of the unpaired Student’s t-test. The 3 top-
scoring pathways of genes up regulated in HCV-related HCC (Panel A), in HCV related non HCC (Panel B) and in Metastatic liver samples (Panel C).
doi:10.1371/journal.pone.0056153.g004
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Cellular growth and proliferation and antigen presentation were
the more important cellular and molecular functions when HCV-
related non HCC samples were compared with normal control liver
tissue. These data agree with the numerous regulatory roles reported
for the HCV core, that affect signal transduction, expression of viral
and cellular genes, cell growth and proliferation [25,26].
Several viruses target specific components of the MHC class I
pathway, leading to diminished cell surface expression of MHC
class I molecules. Other viruses block the transport of MHC class I
molecules through the endoplasmic reticulum (ER), inhibit TAP-
mediated translocation of cytoplasmic peptides into the ER, or
interfere with proteasomal degradation of their own proteins [27].
Other viruses, like human cytomegalovirus, escape CD8_T-cell
recognition by downregulating cellular MHC class I molecules
[28] and simultaneously inducing the expression of virus-encoded
MHC class I homologues capable of engaging inhibitory receptors
that give a negative signal blocking NK cell function. Flaviviruses
can up regulate MHC class I cell surface expression by increased
peptide supply to the ER [29,30]. Viruses may use these strategies
to evade and counteract a potential NK cell attack. Some studies
demonstrated that HCV core protein induced the up regulation of
antigen presentation and immune response mechanisms [31].
Canonical pathways mainly associated with HCV-related non-
HCC tissue included Interferon Signaling, SAPK/JNK Signaling
and NF-kB Activation by viruses pathway. These pathways are
prevalently associated with inflammation and native/adaptive
immunity.
A traditional HCC diagnosis has relied on the use of a single
biomarker approach (e.g., AFP).
Advances in gene expression profiling have provided new
insights into the molecular genetics of HCC, showing strong
expression signatures of cell proliferation and antiapoptosis genes
(such as PNCA and cell cycle regulators CDK4, CCNB1,
CCNA2, and CKS2) along with genes involving ubiquitination
[32], as well as unique molecular markers of progression like
HSP70, CAP2, GPC3, and GS [33]. HCC-specific alterations of
signal transduction pathways and protein expression patterns have
been detected and have led to the development of new therapeutic
agents with molecular targets such as EGFR, VEGF, DDEFL,
VANGL1, WDRPUH, Ephrin-A1, GPC3, Number gain 7q,
PFTK1, PEG10 and miR-122a [34–44].
We based our study on the identification of the minimal set of
genes sufficient for the molecular signature and for developing a
chip able to contribute or substitute the pathology diagnosis and to
furnish a prognostic indication of progression risk, as well as
responsivity to pharmacological treatment of HCV-associated
hepatitis and their progression to cirrhosis/HCC.
Among the four different class comparison analysis (HCV-related
HCC, HCV-related non HCC and Metastatic liver tissue vs.
normal control; HCV-related HCC vs. autologous HCV-related
Table 6.
HCV related HCC tissues versus
normal livers
HCV related non HCC tissues
versus normal livers
Metastatic liver tissues versus normal
livers
Number of differentially
expressed genes Associated
Network Functions (five top-
scored network)
1. Connective Tissue Disorders,
Developmental Disorder, Genetic Disorder
1. Inflammatory Disease, Inflammatory
Response, Renal Inflammation
1. Cellular Assembly and Organization, Genetic
Disorder, Lipid Metabolism
2. Cell Cycle, Cellular Assembly and
Organization, Cellular Function and
Maintenance
2. Cancer, Gastrointestinal Disease, Gene
Expression
2. Cellular Growth and Proliferation, Genetic
Disorder, Neurological Disease
3. Cancer, Reproductive System Disease,
Skeletal and Muscular Disorders
3. Cellular Development, Tissue
Development, Cellular Growth and
Proliferation
3. Developmental Disorder, Genetic Disorder,
Metabolic Disease
4. DNA Replication, Recombination, and
Repair, Nucleic Acid Metabolism, Small
Molecule Biochemistry
4. Cell Cycle, Cellular Assembly and
Organization, DNA Replication,
Recombination, and Repair
4. Cellular Function and Maintenance, Post-
Translational Modification, Cell Signaling
5. RNA Damage and Repair, RNA Post-
Transcriptional Modification, Molecular
Transport
5. Cell Cycle, Cellular Movement,
Endocrine System Development
and Function
5. RNA Post-Transcriptional Modification, DNA
Replication, Recombination, and Repair, Amino
Acid Metabolism
Top molecular and cellular
Function
Gene Expression (1.12E217 to 3.41E203)
1074 genes;
Cellular Growth and Proliferation
(1.04E222 to 4.61E204) 1353 genes;
Gene Expression (6.08E226 to 2.00E204) 1299
genes;
Cellular Growth and Proliferation
(2.00E214 to 3.84E203) 1328 genes;
Gene Expression (2.07E222 to
4.58E204) 1066 genes;
Cellular Growth and Proliferation (1.86E225 to
8.64E205) 1623 genes;
Post-Translational Modification (1.53E209
to 2.45E203) 523 genes;
Cell-To-Cell Signaling and Interaction
(9.05E214 to 4.65E204) 681 genes;
Cell Cycle (5.67E221 to 1.33E204) 818 genes;
Cell Cycle (1.94E208 to 3.81E203) 624
genes;
Cell Death (3.94E213 to 4.59E204)
1032 genes;
Cellular Movement (6.06E221 to 2.17E204)
911 genes;
Cell Morphology (4.44E208 to 4.22E203)
393 genes;
Cellular Movement (1.43E212 to
4.80E204) 745 genes;
Cell Death (9.05E218 to 1.71E204) 1266
genes;
Top canonical pathways Protein Ubiquitination Pathway
(p = 2.88E203);
Interferon Signaling (p = 9.78E204); Arginine and Proline Metabolism
(p = 1.77E209);
14-3-3 mediated Signaling (p = 1.13-E02); Antigen Presentation Pathway
(p = 1.58E203);
Coagulation System(p = 9.68E209);
Aryl Hydrocarbon receptor signaling
(p = 3.09E202)
Protein Ubiquitination Pathway
(p = 2.44E202)
Acute Phase Response Signaling
(p = 2.08E208)
doi:10.1371/journal.pone.0056153.t006
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non HCC liver tissue) we found a gene-set that distinguish the
different cases of liver disease, in particular with time course analysis
we identify the genes that should be candidate as a possible
progression markers (e.g., GPC3, CXCL12, SPINK1, GLUL,
UBD, TM4SF5, DPT, SCD, MAL2, TRIM55, COL4A2). All
these data altogether suggested developing a specific gene-chip
along with genes showing the highest fold up-regulation in common
with previous work representing the different stage of disease.
The identification of the lesions and the evaluation of their
neoplastic progression will be based on the gene pattern expression
on the gene-chip (Figure 5, Table 1–5).
In conclusion we identified a set of genes highly candidate as
gene signatures to be validate on a larger clinical sample size of
liver tissue biopsies to evaluate consistency and universality of the
results, to verify the effective power of distinguishing different
pathological stage of liver disease and to assess their value as
progression markers for early HCC diagnosis in HCV positive
patients. Furthermore, identification of specific alterations in key
metabolic pathways could give the opportunity to identify new
therapeutic targets for innovative, personalized treatments.
Moreover, the gene-expression pattern will be correlated with
additional clinical parameters (besides disease stage and tumor
histopathology) such as the frequency with which patients show the
identified profile, patient age and gender, concurrent diseases and
pharmacological treatments.
In parallel, all our liver collection samples will undergo further
molecular analysis (which include miRNA, aCGH, proteomic) to
develop increasingly sophisticated gene expression indicators of
specific types or stages of liver disease as well as responsivity to
pharmacological treatment of HCV-associated hepatitis and their
progression to cirrhosis/HCC.
Supporting Information
Figure S1 Venn diagram illustrating the number of up-
regulated genes in common between first (green circle)
and second (blue circle) data set. Genes in common are in
red circle. A) Comparison analysis between HCV-related HCC
versus normal liver. B) Comparison analysis between HCV related
non-HCC versus normal liver. C) Comparison analysis between
HCV-related HCC versus autologous HCV related non-HCC.
(TIF)
Table S1 List of the 198 genes upregulated in HCC
samples of the two independent datasets, in comparison
to liver control biopsies.
(XLS)
Figure 5. Molecular signatures in Human Liver Cancer: Hierarchical clustering of the potentially gene markers up-regulated in:
Panel A, HCV-related HCC liver samples (left panel first dataset, right panel second dataset); Panel B, HCV-related non HCC liver
samples (left panel first dataset, right panel second dataset); Panel C, HCV-related HCC; Panel D, metastatic liver samples; Panel E,
genes up-regulated considered possible markers of tumor progression.
doi:10.1371/journal.pone.0056153.g005
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Table S2 List of genes upregulated or down regulated in
metastatic liver lesions in comparison to normal liver
tissue.
(XLS)
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